Hepatocellular carcinoma (HCC) is one of the most common malignant gastroenterological cancers over the world. α-fetoprotein (AFP) is an oncofetal protein produced during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein vaccine, glycoprotein 96 (gp96)/AFP. Our results demonstrated that AFP and gp96 synergistically exhibited significant increase in AFP-specific CD8+ T-cell responses and impressive cytotoxic antitumor effect against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that tumor vaccine by cross-linking tumor antigen and gp96 is a promising approach to cancer therapy.
TangZY. Hepatocellular carcinoma—cause, treatment and metastasis. World J Gastroenterol, 2001; 7:445.
3.
WongR, FrenetteC. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (NY), 2011; 7:16.
4.
HankeP, RabeC, SerweMet al.Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol, 2002; 37:949.
5.
SaekiA, NakaoK, NagayamaYet al.Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma. Int J Mol Med, 2004; 13:111.
6.
ButterfieldLH, KohA, MengWet al.Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res, 1999; 59:3134.
7.
MengWS, ButterfieldLH, RibasAet al.Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol, 2000; 37:943.
8.
GrimmCF, OrtmannD, MohrLet al.Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology, 2000; 119:1104.
9.
HankeP, SerweM, DombrowskiFet al.DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther, 2002; 9:346.
10.
WangXP, LiuGZ, SongALet al.Antitumor immunityinduced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70. World J Gastroenterol, 2004; 10:3197.
11.
MengWS, ButterfieldLH, RibasAet al.alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res, 2001; 61:8782.
12.
WalkerKB, KeebleJ, ColacoC. Mycobacterial heat shock proteins as vaccines: A model of facilitated antigen presentation. Curr Mol Med, 2007; 7:339.
13.
Singh-JasujaH, HilfN, SchererHUet al.The heat shock protein gp96: A receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones, 2000; 5:462.
14.
BinderRJ, HanDK, SrivastavaPK. CD91: A receptor for heat shock protein gp96. Nat Immunol, 2000; 1:151.
15.
LiuB, YeD, SongXet al.A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine, 2008; 26:1387.
16.
ZongJ, PengQ, WangQet al.Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects. Oncol Rep, 2009; 22:953.
17.
AmatoRJ. Heat-shock protein-peptide complex-96 for the treatment of cancer. Expert Opin Biol Ther, 2007; 7:1267.
18.
SchreiberTH, DeyevVV, RosenblattJD, PodackER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res, 2009; 69:2026.
19.
GundryRL, WhiteMY, NogeeJet al.Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics, 2009; 9:2021.
20.
PolaskovaV, KapurA, KhanAet al.High-abundance protein depletion: Comparison of methods for human plasma biomarker discovery. Electrophoresis, 2010; 31:471.
21.
LanYH, LiYG, LiangZWet al.A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma. Cancer Immunol Immunother, 2007; 56:1009.
22.
WangXP, LinHP, WangQX, GuY. Specific antitumor immunity induced by cross-linking complex heat shock protein 72 and alpha-fetoprotein. Cancer Biother Radiopharm, 2012; 27:189.
23.
HankeP, SerweM, DombrowskiFet al.DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther, 2002; 9:346.
24.
HauserH, ShenL, GuQLet al.Secretory heat-shock protein as a dendritic cell-targeting molecule: A new strategy to enhance the potency of genetic vaccines. Gene Ther, 2004; 11:924.
25.
HuangC, ZhaoJ, LiZet al.Multi-chaperone-peptide-rich mixture from colo-carcinoma cells elicits potent anticancer immunity. Cancer Epidemiol, 2010; 34:494.
26.
KeelBA, EddyKB, ChoS, MayJV. Synergistic action of purified alphafetoprotein and growth factors on the proliferation of porcine granulosa cells in monolayer culture. Endocrinology, 1991; 129:217.
27.
VollmerCMJr, EilberFC, ButterfieldLHet al.Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res, 1999; 59:3064.
28.
WangXW, XieH. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci, 1999; 64:17.
29.
LiMS, LiPF, HeSPet al.The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel-7402 cell line. World J Gastroenterol, 2002; 8:469.
30.
SemeniukDJ, BoismenuR, TamJet al.Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule. Adv Exp Med Biol, 1995; 383:255.
31.
BinderRJ, KellyJB3rd, VatnerRE, SrivastavaPK. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J Immunol, 2007; 179:7254.
32.
Mrakovcic-SutićI, JakovacH, SiminMet al.Heat shock protein-GP96 as an innate sensor of damage and activator of autoreactive NKT and regulatory T cells during liver regeneration. Histol Histopathol, 2008; 23:1111.
33.
KroppLE, GargM, BinderRJ. Ovalbumin-derived precursor peptides are transferred sequentially from gp96 and calreticulin to MHC class I in the endoplasmic reticulum. J Immunol, 2010; 184:5619.
34.
LiZ, MenoretA, SrivastavaP. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol, 2002; 14:45.
35.
SrivastavaPK. Therapeutic cancer vaccines. Curr Opin Immunol, 2006; 18:201.
36.
ShinagawaN, YamazakiK, TamuraYet al.Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells. Cancer Immunol Immunother, 2008; 57:165.
37.
MurshidA, GongJ, CalderwoodSK. Heat-shock proteins in cancer vaccines:Agents of antigen cross-presentation. Expert Rev Vaccines, 2008; 7:1019.
38.
SteinhoffU, BrinkmannV, KlemmUet al.Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity, 1999; 11:349.
39.
SrivastavaPK. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol, 2002; 20:395.
40.
BinderRJ, SrivastavaPK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol, 2005; 6:593.
41.
ZhangY, ZanY, ShanMet al.Effects of heat shock protein gp96 on human dendritic cell maturation and CTL expansion. Biochem Biophys Res Commun, 2006; 344:581.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
